The loss of E-cadherin causes dysfunction of the cell-cell junction machinery, which is an initial step in epithelial-to-mesenchymal transition (EMT), facilitating cancer cell invasion and the formation of metastases. A set of transcriptional repressors of E-cadherin (CDH1) gene expression, including Snail1, Snail2 and Zeb2 mediate E-cadherin downregulation in breast cancer. However, the molecular mechanisms underlying the control of E-cadherin expression in breast cancer progression remain largely unknown. Here, by using global gene expression approaches, we uncover a novel function for Cdc42 GTPase-activating protein (CdGAP) in the regulation of expression of genes involved in EMT. We found that CdGAP used its proline-rich domain to form a functional complex with Zeb2 to mediate the repression of E-cadherin expression in ErbB2-transformed breast cancer cells. Conversely, knockdown of CdGAP expression led to a decrease of the transcriptional repressors Snail1 and Zeb2, and this correlated with an increase in E-cadherin levels, restoration of cell-cell junctions, and epithelial-like morphological changes. In vivo, loss of CdGAP in ErbB2transformed breast cancer cells impaired tumor growth and suppressed metastasis to lungs. Finally, CdGAP was highly expressed in basal-type breast cancer cells, and its strong expression correlated with poor prognosis in breast cancer patients. Together, these data support a previously unknown nuclear function for CdGAP where it cooperates in a GAP-independent manner with transcriptional repressors to function as a critical modulator of breast cancer through repression of E-cadherin transcription. Targeting Zeb2-CdGAP interactions may represent novel therapeutic opportunities for breast cancer treatment.
INTRODUCTION
Metastasis is the leading cause of death in breast cancer patients. The epithelial-to-mesenchymal transition (EMT) has a crucial role in metastasis and is highly critical for tumor cell dissemination. One of the hallmarks of EMT is the loss of E-cadherin expression. 1, 2 Therefore, defining the regulatory mechanisms of E-cadherin expression is essential to develop more effective therapeutic strategies to control metastatic cell migration.
Overexpression of the ErbB2 receptor tyrosine kinase has been widely associated with poor prognosis in breast cancer. 3, 4 ErbB2transformed mammary epithelial cells form aggressively growing breast tumors that metastasize to the lungs. 5 A quantitative expression profile of Rho GTPases and their regulators in ErbB2induced mouse breast tumors has identified Rac1 and its negative regulator Cdc42 GTPase-activating protein (CdGAP, also known as ARHGAP31) as the major GTPase and RhoGAP expressed in these tumors. 6 CdGAP regulates both Cdc42 and Rac1 activities, but not RhoA. 7, 8 CdGAP is also a substrate of ERK/GSK-3 and mediates cross talk between the Ras/MAP kinase pathway and the regulation of Rac1 activity. 8, 9 Previous studies have shown that CdGAP is a serum-inducible gene 9 and gain-of-function mutations in the CdGAP gene have been found in patients with the rare developmental Adams-Oliver syndrome (AOS), characterized by the combination of aplasia cutis congenita and terminal transverse limb defects. 10, 11 Importantly, CdGAP is required for transforming growth factor β (TGFβ)-and ErbB2-induced breast cancer cell motility and invasion. 12 Furthermore, a complete loss of E-cadherin expression was impaired in CdGAP-depleted cells during TGFβ-stimulated EMT. 12 However, the mechanism by which CdGAP regulates E-cadherin expression remains unknown. In this study, we report a previously uncharacterized GAP-independent role for CdGAP. CdGAP forms a functional protein complex with the transcriptional repressor Zeb2 to regulate E-cadherin expression in a GAP-independent manner. We correlate this nuclear function with the ability of CdGAP to promote ErbB2-mediated tumor growth and metastasis to the lungs. In addition, high expression of CdGAP correlates with poor prognosis in breast cancer patients. Taken together, this work demonstrates that CdGAP acts as a positive modulator of breast tumorigenesis, offering novel therapeutic perspectives for the treatment of breast cancer.
RESULTS
Identification of a CdGAP-null gene signature in the TGFβ signaling pathway To define how CdGAP regulates E-cadherin expression, we generated CdGAP-deficient stable pooled ErbB2-expressing mouse mammary tumor cells ( Supplementary Figures 1a and b ) and performed next-generation RNA-sequencing (RNA-seq) on these cells, which revealed 1694 differentially expressed genes (fold change 41.6; Adjusted P-value o0.01; of − 16 000 transcripts sequenced) ( Supplementary Figure 2a ; Supplementary  Table 1 ). Global analysis of the expression data revealed genes linked to the TGFβ pathway to be associated with the depletion of CdGAP, including a subset of genes encoding the transcriptional factors Snail1, 13 Zeb2 14 Twist2, ID2 and TGFβ target genes, including E-cadherin (Cdh1), occludin (Ocln) and fibronectin1 (Fn1) (Figures 1a and b ). Our analysis revealed that molecular pathways critical for cancer metastasis, including cell adhesion, basement membrane, angiogenesis, and cell junction were the most significantly affected biological processes in CdGAP-depleted cells (Figure 1c ). Differential mRNA expression of Cdh1, Snai1 and Zeb2 was validated by Quantitative PCR (Q-PCR) and protein level by western blotting (Figures 2a-d) . Moreover, increases of Fn1 and Ocln mRNA levels were confirmed by Q-PCR, whereas Zeb1 mRNA showed no significant change in CdGAP-depleted cells ( Supplementary Figure 2b) .
In good agreement with the changes observed in the expression of TGFβ target genes, the characterization of CdGAPdepleted cells revealed epithelial-like morphological changes. In contrast to diffuse cytoplasmic E-cadherin localization in control breast cancer cells, E-cadherin staining was enriched at cell-cell junctions in CdGAP-depleted cells (Figure 3a ). E-cadherin fluorescence intensity measured along a 7-μm segment showed a shift of E-cadherin to the cell periphery in CdGAP-depleted cells compared with control cells (Figure 3b ). Actin enrichment characterized by membrane ruffles was also observed at the leading edge of CdGAP-depleted cells, even though active Rac-GTP levels were not significantly altered compared to control cells (Figures 3c and d) . Therefore, these results demonstrate that the loss of CdGAP restores E-cadherin localization at cell-cell junctions in breast cancer cells.
CdGAP represses the E-cadherin promoter activity in a GAP-independent manner We next hypothesized that CdGAP could directly repress E-cadherin expression through a transcriptional mechanism. To accomplish this, we employed luciferase reporter constructs controlled by E-cadherin promoter that were introduced into ErbB2-expressing breast cancer cells or in HEK293 cells. In agreement with our hypothesis, CdGAP-depleted breast cancer cells showed a fivefold increase in E-cadherin promoter activity BMP2  TWIST2  CRB3  TGFB2  TGFB3  COL6A1  COL6A2  OCLN  FN1  ITGB6  CDH1  GADD45B  ID2  TGFBR1  MMP28  SPARC  CTGF  ARHGEF18  JUN  SERTAD2  ZEB2  SNAI1  GDF11  ITGA5  TGFBR3  COL5A1  GDF15  CDKN2A  MMP3  MMP10  BMP7   - compared to control cells (Figures 4a and b ). The expression of human CdGAP (hCdGAP) in CdGAP-depleted cells was able to partially restore E-cadherin transcriptional repression, without significantly modifying the endogenous levels of Zeb2 expression when compared to cells transfected with empty vector (Figures 4a and b ). However, 48 h posttransfection, the expression of hCdGAP was able to restore the levels of Zeb2 in CdGAP-depleted cells comparable to control cells ( Figure 4c ). CdGAP consists of an N-terminal GAP domain, a basic central region followed by a proline-rich domain (PRD). 12 Figure 5a ). To delineate the regions within CdGAP that enable the association with Zeb2, CdGAP deletion mutants were expressed with Flag-Zeb2 in HEK293 cells and the association was assessed by coimmunoprecipitation. CdGAP, CdGAP-PRD or CdGAP-ΔGAP but not CdGAP (1-683) associated with Zeb2 ( Figure 5b ). Thus, these results demonstrate that an intact PRD is required to suppress E-cadherin expression and mediate the interaction between CdGAP and Zeb2.
As Zeb2 localizes exclusively in the nucleus in several cell lines, 16 
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Relative Luciferase Activity Relative Luciferase Activity 23.77 (±1.21)% of GFP-CdGAP-expressing cells showed a mixed nuclear and cytoplasmic localization (Figures 5c and d ). However, when GFP-CdGAP and myc-Zeb2 were co-expressed in cells, we observed a significant relocalization of GFP-CdGAP from the cytoplasm to the nucleus. Indeed, 73.35% of GFP-CdGAP and Myc-Zeb2 co-expressing cells displayed nuclear CdGAP localization, while cytoplasmic localization was reduced to 5.58% of coexpressing cells (Figure 5d ; Supplementary Figure 3 ). Accordingly, the majority of GFP-CdGAP was detected in the nuclear fraction following subcellular fractionation experiments and overexpression of Myc-Zeb2 increased the levels of GFP-CdGAP in the nuclear fraction ( Figure 5e ). We next assessed whether CdGAP interacts with the E-cadherin promoter by binding to the central core 5′-CACCTG-3′ (E-box) element 17 using chromatin immunoprecipitation assays. CdGAP interacted with the E-cadherin promoter and co-expression with Zeb2 did not further increase the binding to the promoter (Figure 5f ). Taken together, these results demonstrate that CdGAP localizes with Zeb2 in the nucleus and is capable of interacting with the E-cadherin proximal promoter region to repress transcription.
CdGAP is required for ErbB2-induced tumor growth and metastasis to the lungs To further examine the role of CdGAP in vivo, pooled ErbB2expressing control and CdGAP-depleted tumor cells were injected into the mammary fat pads of athymic mice. Six weeks postinjection, the loss of CdGAP led to a 75% reduction in primary tumor volume compared to tumors formed in mice injected with control cells (Figure 6a ). Histological analysis of the primary tumors confirmed reduced CdGAP expression and increased E-cadherin expression in CdGAP-depleted compared to control tumors (Figures 6b and c) . To better understand how CdGAP influenced tumor growth, we performed TUNEL staining and examined the cell proliferation Ki67 marker by immunohistochemistry (IHC). Cell proliferation was reduced by 2.5-fold in CdGAP-depleted tumors (Figure 6d ). In contrast, CdGAP depletion did not induce cell apoptosis in these tumors ( Supplementary  Figure 4a ). Next, we determined whether CdGAP is required to promote lung metastasis of ErbB2-expressing breast cancer cells. An equal number of ErbB2-expressing control or CdGAP-depleted cells was injected directly into the mouse lateral tail vein. After 4 weeks, 90% of the mice injected with control cells developed multiple lung metastases, while only 10% of the mice injected with CdGAP-depleted cells formed small metastatic lesions (Figure 6e ). Altogether, these results indicate that CdGAP is necessary for the growth and metastasis of ErbB2-expressing breast cancer cells.
High expression level of CdGAP is associated with poor clinical outcome for breast cancer patients To assess the clinical relevance of CdGAP in human breast cancer, we examined CdGAP protein expression in a panel of human breast cancer epithelial cell lines. As shown in Figure 7a , CdGAP expression was detected in normal mammary epithelial MCF10A cells but was absent or barely detectable in MCF7 or T47D cells derived from luminal A breast cancers. Except for the basal A BT20 cell line, CdGAP was highly expressed in cells derived from basallike tumors, in particular within claudin-low basal-like cancer cells. 18, 19 We also found an inverse correlation between CdGAP and E-cadherin expression levels in luminal A and basal B breast cancer cell lines, consistent with our results obtained in ErbB2expressing breast cancer cells (Figure 2b ). Furthermore, CdGAP overexpression in MCF7 cells, which have low CdGAP expression, significantly increased SNAIL1 and ZEB2 mRNA expression levels while decreasing E-cadherin mRNA and protein levels (Figures 7b  and c) . Conversely, siRNA-mediated CdGAP knockdown in MDA-MB-231 cells, which express high levels of CdGAP, decreased SNAIL1 and ZEB2 mRNA levels while increasing E-cadherin mRNA and protein levels (Figures 7d and e ). In addition, the loss of CdGAP in MDA-MB-231 cells induced a morphological change from a spindle-shaped, mesenchymal form in control cells to a rounded, epithelial-like morphology in CdGAP-depleted MDA-MB-231 cells (Figure 7f) . A cortical pattern of F-actin staining, which is a hallmark of the epithelial morphology, 1 was also observed in CdGAP-depleted MDA-MB-231 cells (Figure 7f ). Consistent with the increased E-cadherin levels detected in CdGAP-depleted MDA-MB-231 cells (Figures 7d and e ), we observed an increased E-cadherin fluorescence intensity in CdGAP-depleted MDA-MB-231 cells compared to control cells (Figure 7g ). We also examined the effect of Myc-Zeb2 overexpression on endogenous CdGAP localization in MDA-MB-231 cells by subcellular fractionation experiments (Figure 7h ). Endogenous CdGAP was predominantly found in the cytoplasmic fraction of MDA-MB-231 cell lysates and overexpression of Myc-Zeb2 in MDA-MB-231 cells led to an increase of endogenous CdGAP in the nuclear fraction ( Figure 7h ). Next, we performed a molecular subtype analysis of transcriptional profiles using a large compendium of breast cancer data sets with tumor gene expression profiles and clinical annotations (n = 3666). 20 A significantly higher level of CdGAP mRNA expression was found in ER − /HER2 − basal-like breast cancer patients compared to Her2 + , Luminal A or Luminal B subtypes (Kruskal-Wallis test p = 1.1E − 35) ( Figure 8a ). Moreover, using the cBioPortal for Cancer Genomics (www.cbioportal.org), 21 we found a strong correlation (Pearson = 0.74, Spearman = 0.81) between CdGAP and Zeb2 mRNA expression, based on the RSEM (RNA-Seq by Expectation-Maximization) values of the transcripts in 963 samples from a breast invasive carcinoma study (TCGA, provisional) ( Figure 8b ), further supporting the molecular interaction between CdGAP and Zeb2 observed in breast cancer cells (Figure 5a ). We next performed IHC on a panel of breast tumors using tissue microarray analysis (TMA) to assess CdGAP expression in breast cancer patients (n = 353). 74% of the breast tumor specimens showed a moderate to strong cytoplasmic CdGAP expression, while 26% displayed weak to no CdGAP expression ( Figure 8c ). Consistent with CdGAP localization in human breast cancer cells, CdGAP was detected both in the cytoplasm and nucleus of breast tumors (Figure 8d ). 51.3% of breast tumors showed predominantly a cytoplasmic localization and 43.9% of the tumors presented a mixture of cytoplasmic and nuclear localization, while only 4.8% of the tumors exhibited an exclusive nuclear localization of CdGAP (Figures 8d and e ). We then examined the relationship between CdGAP mRNA expression and the survival probability in breast cancer patients according to clinical subtypes using a large data set of microarray analysis linked to clinical outcome (n = 1190). 20 As shown in Kaplan-Meier survival analysis of patients classified based on CdGAP expression, high CdGAP expression was associated with poor disease-free survival in all subtypes of breast cancer patients (n = 1190, logrank P = 4.1E − 4), and specifically in ER + /HER2 − low proliferation (Luminal A) subtype (n = 333, logrank P = 7.1E − 4) (Figure 8f; Supplementary Figure 4b ). Overall, these results indicate that CdGAP is frequently overexpressed in breast cancer tumors and high CdGAP expression is associated with a poor prognosis for the patients.
DISCUSSION
During the process of epithelial-to-mesenchymal transition in cancer cells, the loss of E-cadherin expression, which results in the disruption of adherens junctions, correlates with increased cell migration, invasion, cancer metastasis and a poor clinical outcome in patients with cancer. 15, 22 The study presented here identifies a gene signature composed of the TGFβ signaling pathway and EMT genes under the control of CdGAP in ErbB2-expressing breast cancer cells. We demonstrate that CdGAP acts as a novel cotranscriptional repressor with Zeb2 to suppress E-cadherin expression in breast cancer cells. Consequently, this work reveals an unexpected GAP-independent role for CdGAP as a positive modulator of breast tumorigenesis and metastasis (Figure 9 ). This is in marked contrast with the paradigm that GAPs are often seen as tumor suppressor proteins through their negative regulation of Rho GTPases. 23 Notably, the RhoGAP protein DLC1 (deleted in liver cancer 1) serves as a tumor suppressor protein by inactivating RhoA in various cancer types. 24, 25 On the other hand, overexpression of DLC1 prevents cell migration, invasion and metastatic cancer progression. 24 However, recent studies have also suggested that DLC1 can function as a scaffolding protein to affect cell survival and cell motility in a GAP-independent manner. 26 ARHGAP30, a GAP for RhoA and Rac1, 27 has been found to suppress cell migration and invasion in colorectal cancer through the regulation of p53 acetylation independently of its GAP activity. 28 Here, we demonstrate that the mechanism by which CdGAP binds with Zeb2 and represses E-cadherin promoter activity does not involve its GAP domain but the PRD. Therefore, this is suggesting that the modulation of Rac1/Cdc42 GTPase activities is not required for CdGAP transcriptional function and its ability to induce breast tumorigenesis and metastasis to the lungs. This work also supports our previous findings that the CdGAP-PRD is sufficient to mediate TGFβ-induced cell migration and invasion in breast cancer cells. 12 The truncated CdGAP (1-683) mutant protein, lacking the C-terminal tail and part of the PRD, was first identified in autosomal-dominant AOS patients and was shown to display increased GAP activity in vitro towards Cdc42, suggesting that the disease mutations in the CdGAP gene behave as dominant gain-offunction alleles. 10 In the present study, we demonstrate that this AOS-related CdGAP mutant is not able to repress E-cadherin transcription, raising the interesting possibility that additional regulatory mechanisms independent of Rac1/Cdc42 regulation may also explain the rare developmental abnormalities of AOS patients. Furthermore, mutations in several genes of the Notch signaling pathway, including EOGT, RBPJ, Notch1 and the Notch ligand Dll4, have recently been identified in AOS patients. [29] [30] [31] [32] In addition, a recent study revealed a VEGF-regulated Snail1-Dll4/ Notch axis to control vascular development. 33 VEGF modulates Dll4 expression by co-inducing the transcriptional repressor Snail1 via the ERK/AKT-dependent inactivation of GSK-3β. 33 Of interest, we show here that CdGAP regulates the levels of Snail1 transcripts in breast cancer cells. Genes of the Notch signaling pathway, including Notch4, Dll4 and MAML2, were also identified under the control of CdGAP (Supplementary Table 1 ). It is noteworthy that we have recently found CdGAP as a critical regulator of vascular development and VEGF-mediated angiogenesis. 34 In this way these findings support an emerging link between the novel transcriptional activity of CdGAP and the potential regulation of the Notch signaling pathway in the control of vascular development, angiogenesis and cancer metastasis.
In patients with breast cancer, we found a significant high expression level of CdGAP in ER − /HER2 − basal-like breast cancer patients. Furthermore, CdGAP expression strongly correlated with Zeb2 expression in patient samples from a breast invasive carcinoma study. Thus, these data strongly support the novel nuclear function of CdGAP in breast cancer cells. Furthermore, high CdGAP expression correlated with poor prognosis, in particular in the luminal A subtype, which tends to be the subtype with fairly high survival rates and low recurrence rates. 35, 36 Therefore, we propose that CdGAP could serve as a novel biomarker to identify luminal A subtype patients at higher risk and targeting CdGAP-Zeb2 interactions may help to define novel therapeutic strategies to treat breast cancer patients.
MATERIALS AND METHODS

Cell culture, DNA constructs and transfections
NMuMG-derived ErbB2-expressing mammary tumor explant cells were cultured as previously described. 5, 12 Briefly, activated forms of the ErbB-2 receptor were individually transfected into an immortalized mammary epithelial cell line (NMuMG), along with an empty vector control. Pooled stable transfected cells were injected into the mammary fat pads of athymic mice. Activated ErbB2-expressing tumor cells were explanted back into culture from ErbB2-expressing mammary tumors. ErbB2-expressing tumor explants cells with stable expression of short hairpin RNAs targeting CdGAP were generated using the pSuper retro GFP/neo retroviral shRNA expression vector (Oligoengine, Seattle, WA, USA). Hairpins were derived from the template sequence: 5′-GGGACCAUCUGGUAUACAAtt-3′. 12 HEK293 cells, human breast cancer cell lines were routinely culture as previously described. 12, 18 CdGAP and Zeb2 constructs were as described previously. 12, 16, 37 pGL2Basic-EcadK1/EpaIMUT/EboxMUT/Ebox2MUT in the luciferase assay was a gift from Eric Fearon (Addgene plasmid # 19291). pGL2Basic-pEcad (−1008/+49) was a gift from Morag Park. HEK293 cells were transfected by the Polyethylenimine method, whereas Lipofectamine 2000 was used for transfection of ErbB2-expressing explants tumor cells, MCF7 and MDA-MB-231 cells. siRNAs for CdGAP knockdown in human breast cancer cell lines were described previously. 34 Western blotting and immunofluorescence 
Rac1 activation assay
The Rac1 activation assay was performed as previously described. 37 mRNA Isolation, RNA-sequencing and analysis mRNA Isolation, RNA-sequencing were performed as previously described. 6 Briefly, total RNA from three independent samples of ErbB2-expressing control (shCON) or CdGAP-depleted (shCdGAP) explants cells was extracted using TRIZOL reagent (Invitrogen, Burlington, ON, Canada) and cleaned up using a RNeasy column. 39 Differential gene expression was then quantified with Cuffdiff (v 2.2.1). 40 Both the reference genome and the annotations were downloaded from Ensembl. For the analysis, genes were considered significantly differentially expressed when the adjusted Po 0.01 and the fold change was either o0.625 or 41.6 and the average count 440. For the DAVID analysis, only the genes found to be upregulated in the CdGAPdepleted cells were submitted (fold change 41.6) and the Functional Annotation Clustering tool was used. The map of the TGFβ pathway was generated in Ingenuity Pathway Analysis and was annotated by hand and genes were considered differentially expressed when the adjusted P o0.01 and the average count 440.
Quantitative real-time PCR
Total RNA were extracted using RNeasy mini kit. mRNA was reversetranscribed using enzymes from Invitrogen. Quantitative Real-Time PCR (Q-PCR) was performed as described previously 12 using primers listed in Supplementary Table 2 . All Q-PCR were performed using Power SYBR Green PCR Master Mix (Invitrogen). Gene expression was normalized to 18S ribosomal subunit. Each sample was analyzed in triplicates.
Luciferase assays
ErbB2-expressing breast cancer cells (shCON or shCdGAP) or HEK293 cells were co-transfected with human wild-type E-cadherin-luc (−1008/+49) or E-box mutant E-cadherin-luc plasmids together with the CdGAP and/or Zeb2 constructs. The luciferase assays were performed 20 h posttransfection as described previously. 16 
Subcellular fractionation
Nuclear and cytoplasmic fractions were prepared using the NE-PER nuclear and cytoplasmic extraction reagents kit (Thermo Fisher Pierce, Waltham, MA, USA) according to the manufacturer's protocol.
Chromatin immunoprecipitation
Chromatin immunoprecipitation assays were conducted as described previously. 41 Soluble chromatin was immunoprecipitated using GFP (Invitrogen) or Myc antibodies (Millipore). A 251bp fragment in the proximal E-cadherin promoter or a 207 bp fragment in the upstream region of the CDH1 gene as a negative control were amplified with primers described in Supplementary Table 2 
Tumorigenesis and metastasis assay
To assess primary tumor growth of the pooled ErbB2-expressing breast cancer cells, 1 10 6 cells were injected into the number 4 mammary fat pad of female athymic mice. Tumor volumes were calculated using the formula: V = π (length × width 2 )/6. For tumor metastasis assay, 2 × 10 5 cells were directly injected into the lateral tail veins of athymic mice. 
TMA construction
Each tissue block had a corresponding H&E-stained slide. Representative areas of invasive carcinoma were identified and marked on the H&E slide and its corresponding tissue block. The TMAs were assembled with a tissue-arraying instrument (Beecher Instruments, Silver Springs, MD, USA), as described elsewhere. 42, 43 Briefly, the area of interest in the donor block was cored twice with a 0.6-mm diameter array needle and transferred to a recipient paraffin block for construction of a twofold redundant tissue microarray block. Three TMA blocks were designed. 1.10. 44 The processed score data were then analyzed with the SPSS for Windows statistical software package (Microsoft, Redmond, WA, USA).
Immunohistochemistry
Compendium of microarray breast cancer data sets
We retrieved all clinical and gene expression data of previously reported microarray data sets as published in Haibe-Kains et al. 20 To ensure comparability of expression values across multiple data sets, ESR1, ERBB2 and AURKA gene expression module scores were rescaled prior to applying the subtype classifier as in Azim et al. 45 (we used SCMOD1 classifier which is referred to as SCM in the present study). Our rescaling approach is implemented and fully documented in our R/Bioconductor package genefu version 1.5.2. Differences in expression of CdGAP according to subtype was examined using the Kruskal-Wallis test.
Survival analysis
All survival analyses have been performed with R version 2.15 using the survival package version 2.36-14. Distant metastasis-free survival was the primary survival end-point, which is defined as the time elapsing between breast cancer diagnosis and date of local or systemic relapse, or death. When distant metastasis-free survival data were not reported, relapse-free survival information was used if available. All survival data were censored at 10 years to ensure similar follow-up across the different data sets that are part of our compendium. 46 Survival plots according to the CdGAP tertiles were drawn using the Kaplan-Meier method, and the significance of the survival differences were evaluated using the logrank P-test.
Statistical analysis
Statistical analysis was performed using a two-sample unequal-variance Student's t-test. Data are presented as the mean ± s.e.m.
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Tumorigenesis metastasis E-Box PRD PBR GAP BR Figure 9 . Model of CdGAP as a novel transcriptional co-repressor of E-cadherin expression. CdGAP interacts with Zeb2 and acts as a negative transcriptional co-factor to repress E-cadherin expression, resulting in EMT, tumorigenesis and metastasis.
